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Sickle cell disease (SCD) is the most common inherited haematological disorder, producing a mutation of the haemoglobin 
molecule known as haemoglobin S (HbS). The presence of HbS in the erythrocyte makes it prone to sickling — a process that 
may lead to vaso-occlusive injury, haemolysis and a hypercoagulable state. Sickling is precipitated by dehydration, hypoxia, 
hypothermia, acidosis and low flow situations. Over time, multi-organ damage develops with significant morbidity and mortality.
Paediatric patients with SCD and congenital heart defects may require anaesthesia for corrective cardiac surgery on 
cardiopulmonary bypass (CPB). During the perioperative period these high-risk patients may suffer significant complications 
when exposed to the conditions that favour erythrocyte sickling.
This case series details experience of four paediatric patients with SCD who underwent corrective cardiac surgery at Red 
Cross War Memorial Children’s Hospital. The pathophysiology is discussed and the perioperative management of transfusion, 
cardiopulmonary bypass and temperature regulation is highlighted.
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Introduction
Patients with sickle cell disease (SCD) presenting for cardiac 
surgery requiring cardiopulmonary bypass (CPB) pose a unique 
perioperative challenge when exposed to conditions that can 
elicit erythrocyte sickling with potentially fatal complications.
Literature on the optimal management of these patients is 
limited, and most contributions on this topic are retrospective 
case reports or small series.1,2 In this case series and discussion, 
we endeavour to heed the call by Mennes et al: ‘To increase the 
available evidence, every experience with cardiac surgery in 
sickle cell disease patients should be reported.’3
Methods
Following approval from the Departmental Research Committee 
and the University of Cape Town Research Ethics committee, a 
retrospective review of data on patients with SCD who 
underwent cardiac surgery was conducted. A total of four 
patients were identified between April 2004 and May 2013. 
Seven cardiac surgical procedures were performed, six requiring 
CPB. In the decade preceding this review, only one patient with 
SCD underwent cardiac surgery.
Relevant patient information and clinical parameters were 
collected from the patient records and analysed.
Anaesthetic management
Perioperative management differed between patients. A 
description of the management principles for these cases is 
discussed and pertinent information highlighted.
Patients were prepared and optimised for surgery in the 
Paediatric Intensive Care Unit (PICU) in collaboration with the 
surgeons, cardiologists, haematologists and intensivists involved. 
Regular medication was continued until the day of surgery. Oral 
intake was stopped four hours prior to surgery and intravenous 
fluid, calculated according to body weight, was initiated. Sedative 
premedication was not routinely administered. Red cell 
transfusion prior to surgery was individualised for each patient.
Anaesthesia was induced with inhalation of a sevoflurane and 
oxygen mixture and intravenous fentanyl (5–10  mcg/kg) and 
pancuronium (0.1 mg/kg) was administered. Following tracheal 
intubation anaesthesia was maintained with 1% isoflurane in 
oxygen and air. Incremental doses of fentanyl (up to 25 mcg/kg) 
were given.
Invasive monitoring, arterial line and central venous access, was 
inserted once the patient was deeply anaesthetised. Prophylactic 
antibiotics were given prior to surgery and repeated four hourly. 
Heparin 300–400 units/kg was administered prior to bypass and 
activated clotting time (ACT) was monitored to achieve a 
value > 480 seconds.
Arterial blood pressure, central venous pressure, electrocardiogram, 
saturation with pulse oximetry, and rectal temperature were 
routinely monitored during and after surgery. Cerebral near-
infrared spectroscopy (NIRS) was introduced as routine monitoring 
for cardiac patients in 2007. Patients were transferred to the ICU 
intubated, and, to achieve sedation and analgesia, infusions of 
midazolam and morphine were initiated. Patients were monitored 
in the ICU and, once haemodynamic, pulmonary and cognitive 
function was optimised, weaned from ventilation and extubated.
Cardiopulmonary bypass
The bypass circuit was primed with a combination of crystalloid, 
colloid and red blood cells (RBC) to achieve a haematocrit level of 
30%. To the prime solution, 2000 units of heparin, 10  ml of 
sodium bicarbonate and 4  ml calcium gluconate per unit of 
blood were added. The prime was oxygenated to > 50 kPa before 
bypass was initiated and maintained throughout the procedure, 
while venous oxygen saturation was kept at or above 80%. 
Patients were cooled to 32–34°C. Arterial pH was kept between 
7.34 and 7.44 using α-stat. Full flow was calculated using the 
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patient’s height and weight. Routine cardioplegia at this time 
was crystalloid St Thomas solution.
Results
All patients in this series were immigrants from central Africa 
undergoing corrective cardiac surgery for congenital heart 
disease (CHD). Of the seven procedures performed, two required 
redo-surgery following breakdown of the ventricular septal 
defect (VSD) patch. Respiratory complications were limited to 
one episode of collapsed consolidation of the left lung requiring 
prolonged ventilation. None of the patients developed acute 
chest syndrome (ACS). Three cases had coexisting pulmonary 
hypertension (PHT), and in one case it persisted following 
surgery. The combination of longstanding severe SCD and CHD 
made the treatment of PHT particularly complex.
Data on cooling on CPB was incomplete, but interestingly case 4, 
performed in 2013, was cooled to 34°C, possibly reflecting the 
trend towards mild hypothermia during CPB in SCD cases.1,4–7
A limitation of retrospective data collection from patient folders 
is that key information is often not available. For instance, it is not 
clear whether perioperative HbA/HbS concentrations were 
monitored, or when erythrocyte transfusions were performed. 
Cases 1 and 4 had preoperative HbS concentrations of 97% and 
48% respectively. Both these patients had preoperative exchange 
transfusions. All patients had intraoperative transfusions at 
initiation of CPB. All patients were discharged home following 
surgery, but further outcome data are lacking (see Table 1).
Discussion
Epidemiology
The global number of SCD newborns reached 305 800 in 2010, 
with sub-Saharan Africa accounting for 79% of the total.2 The 
incidence in South Africa remains low, but recent research at Red 
Cross War Memorial Children’s Hospital (RCWMCH) haematology 
clinic demonstrated a sharp increase (300%). This is likely due to 
the changing population demographics and immigration from 
Central African countries where the disease is most prevalent.8 
The global prevalence of SCD is predicted to increase, and, along 
with improved screening programmes, diagnostic and treatment 
modalities, more patients with SCD may require cardiac surgery 
in the future.9
Genetics
SCD is the most common monogenic disease in humans and also 
the most common inherited haematological disorder.8,10 The 
affected gene is located on chromosome 11, which codes for the 
β-globin chain of haemoglobin A (HbA). A single point mutation 
on this gene results in the β-globin chain losing part of its 
negative charge, changing the solubility and stability of the 
haemoglobin (Hb) molecule. The Hb constructed of this mutated 
β-globin chain (Figure 1) is referred to as haemoglobin S 
(HbS).3,11,12
Inheritance is autosomal recessive. The homozygotic phenotype 
is known as sickle cell anaemia (SCA) and contains HbS (80-98%) 
and some HbF. The heterozygous phenotype contains normal 
HbA (60–65%), HbS (35–40%) and some HbF, and is referred to as 
sickle cell trait (SCT) (see Figure 2). SCA presents with more 
frequent symptoms and the disease process may be severe and 
progressive.3,10,12,13
Pathophysiology
In affected individuals erythrocytes may sickle when HbS 
becomes deoxygenated leading to a conformational change and 
polymerisation of the haemoglobin molecule. This stiffens and 
disrupts the erythrocyte’s structural integrity (‘sickling’) making it 
less pliable and more prone to aggregation, vascular occlusion 
and haemolysis. The degree of polymerisation and sickling is 
dependent on two aspects: the duration of deoxygenation and 
the total HbS concentration. Hypoxia, hypothermia, acidosis and 
Table 1: Patient demographics and clinical characteristics
SCA = sickle cell anaemia; SCT = sickle cell trait; Wt = weight; Ht = height; AoX = aortic cross clamp; CPB = cardiopulmonary bypass; VSD = ventricular septal defect; PDA = 
patent ductus arteriosus; Ao = aorta.
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low flow states are classically described as triggers for sickling. 
However, recent research suggests that more complex processes 
are at play.3 Once erythrocyte sickling and vascular occlusion 
occurrs, secondary endothelial inflammation, activation of 
coagulation and increased expression of adhesion molecules 
such as vascular cell adhesion molecule-1 (VCAM-1), P-selectin 
and E-selectin leads to progressive microvascular occlusion. 
When blood flow to the affected tissues is restored, reperfusion 
injury occurs with characteristic free radical production, oxidant 
stress and the release of platelet activating factor (PAF). Repetitive 
cycles of ischaemia–reperfusion injury lead to multi-organ failure 
associated with SCD.10,13,14
Haemolysis can lead to clinically significant anaemia, but also 
contributes to endothelial inflammation through the release of 
Hb and arginase-1 into the plasma.12 Free plasma Hb scavenges 
nitric oxide (NO) while arginase-1 metabolises the NO precursor, 
L-arginase, leading to endothelial dysfunction and worsening 
microvascular disruption.3,14
Dysregulation of coagulation leads to a hypercoagulable state 
due to activation of platelets, tissue factor and increased platelet 
numbers12,15–17 (see Figure 3).
Complications
Over time, ischaemia–reperfusion, haemolysis and 
hypercoagulability result in a multisystem disease with numerous 
complications. These are listed with the associated features in 
Table 2.10,12,13,15,17–23
Treatment
Treatment of SCD frequently involves erythrocyte transfusion 
that increases total Hb concentration, enhances oxygen delivery 
and improves tissue oxygenation. It also decreases endogenous 
erythropoiesis, and in this way reduces HbS production. This has 
been shown to decrease complications associated with SCD, but 
the risk of acute transfusion reactions and allo-immunisation are 
increased.3,12,22–24
Common indications for transfusion include:
•  acute symptomatic anaemia
•  aplastic crises
•  acute sequestration crises by the spleen or liver
•  stroke
•  acute chest syndrome (ACS)
Medical management of SCD with hydroxyurea increases HbF 
concentration and has been shown to decrease the frequency of 
painful episodes, ACS, the need for blood transfusion, and 
admission to hospital. Stem cell transplant and gene therapy are 
reserved for selected cases, usually when other treatment 
modalities have failed.12,23
Perioperative considerations
Preoperative assessment and preparation
A thorough history and examination to evaluate disease severity 
and the extent of end-organ damage is essential. SCA is more 
severe than SCT, as is the African haplotype compared with the 
Asian. Frequency of painful symptoms, ACS and hospital 
admissions are associated with increased risk of perioperative 
complications. Intercurrent infection needs to be excluded, as 
this can trigger sickling events and ACS. Appropriate special 
investigations should be directed by clinical suspicion of 
complications and end organ-damage (see Table 2). Recent 
blood test for Hb level, urea–electrolytes–creatinine, chest X-ray 
(CXR), and urine dipsticks would be appropriate for most cases.3,22
Figure 1: Formation of haemoglobin A, S and F.
Figure 2: Sickle cell disease genotypes.
Figure 3: Pathophysiology of sickle cell disease.
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Table 2: Complications of sickle cell disease
Complication Features
Vaso-occlusive crisis (VOC)
Severe painful episodes associated with vaso-occlusionHigh incidence in:
•  Homozygous variant
•  High haematocrit
•  Low haemoglobin F
•  Nocturnal hypoxemia
•  Sibling history of asthma
Pulmonary
Acute chest syndrome (ACS)
Causes:
•  Pulmonary infection
•  Fat embolism
•  Intravascular pulmonary sequestration of sickled erythrocytesChest 
X-ray features:
•  New pulmonary infiltrate, consistent with alveolar consolidation 
involving at least one complete lung segment
Pulmonary hypertension (PHT)
Major risk factor:Severe haemolytic anaemiaMarkers of haemolysis:
•  Low steady state haemoglobin
•  High lactate dehydrogenase
•  High bilirubin
•  High reticulocyte countOther causes:
•  Iron overload
•  Hepatitis C
•  Porto-pulmonary hypertension
•  Thromboembolism
•  Chronic renal failure
•  Recurrent ACS
Reactive airway disease Worsening with ageResults in increased pulmonary artery pressure
Cardiovascular
Left ventricular (LV) dilation/hypertrophy & diastolic dysfunction
Consequences of chronic anaemia
•  Increased LV stroke volume, increased cardiac output & heart rate
•  LV dilatation may develop and progress to LV hypertrophy with 
decreased LV filling and diastolic dysfunction
Myocardial infarction/dysrhythmias May develop during vaso-occlusive crisis
Acute right ventricular failure Secondary to vaso-occlusive crisis or acute chest syndrome
Renal
Renal impairment
Erythrocyte predisposed to sickling in renal circulation due to:
•  Low flow state
•  Low partial pressure oxygen
•  High oxygen extraction
•  Low pH
•  High osmolality leading to cellular dehydration
Recurrent UTI Common trigger of acute chest syndrome
Neurological
Cerebrovascular accident (CVA)




•  Abnormal rheology causing endothelial damage
•  Functional NO deficiency associated with haemolysis
•  Impaired regulation of blood flow causing hyperaemia
Subarachnoid and intracranial haemorrhage – 26% mortality in two weeks
Immunological
Infection
Prone to infection due to:
•  Impaired splenic function
•  Defect in complement activation
•  Micronutrient deficiency
•  Tissue ischaemia
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The largest case series of 47 SCD patients included 21 paediatric 
patients who received either preoperative or intraoperative 
exchange transfusion, or both. Intraoperatively, a haematocrit of 
30% and an HbS  <  10% was targeted using a combination of 
RBC, crystalloid and colloid CPB prime, the volume of which was 
calculated using the patient’s age, weight and body surface area 
(BSA). The prime was oxygenated to > 50 kPa before initiation of 
CPB and maintained during bypass. Venous oxygen saturation 
was maintained between 75% and 80%, with a targeted pH of 
7.34–7.44. Of these cases, none developed sickling.1,4 This 
approach seems to combine the benefits of perioperative 
transfusion and appropriate CPB set-up effectively to limit the 
potential for adverse events.
At RCWMCH a similar approach to the one described above was 
followed.
The principle of perioperative transfusion is to improve oxygen 
delivery by increasing the HbA concentration, and limit sickling 
potential by decreasing HbS concentration. Whether a SCD 
patient is transfused pre-or intraoperatively will depend on his/
her current clinical condition and local protocol. The sickling risks 
are much lower in SCT patients and intraoperative transfusion 
alone may be a safe option.
Allo-immunisation
Erythrocyte allo-immunisation is the most common transfusion-
related complication in SCD patients and may lead to life-
threatening haemolytic disease in the foetus and newborn 
(HDFN), acute haemolytic transfusion reactions (AHTR), and 
delayed haemolytic transfusion reactions (DHTR). A higher rate 
of allo-immunisation after multiple transfusions is seen in SCD 
compared with the general population. This may be due to 
phenotypic incompatibility between the predominantly black 
SCD patients and the predominantly white donors described in 
European and American literature. Indeed, the incidence in 
Uganda, Nigeria and Jamaica is much lower, where racial 
antigenic homogeneity between donors and recipients is 
greater.4,27–30
Recent research showed that extended donor/recipient 
matching reduces allo-immunisation significantly. A large single-
centre study found that specifically matching C, E, D, Kell, Kidd, 
and Fy-a antigens dramatically decreased the incidence. 
Subsequently, the Blood Transfusion Service made 
recommendations to perform extended antigen matching for all 
SCD patients and to issue the closest phenotypically matched 
blood available.31 This process may take longer, and blood 
Special considerations:
•  Pulmonary hypertension is increasingly recognised as a 
perioperative risk factor and poor prognostic indicator.17,25
•  Hydroxyurea treatment may cause bone marrow 
suppression. If suspected, discuss with a haematologist.22
•  Order blood products well in advance. The blood bank 
needs to perform extended antigen matching.
•  Discuss the case with the cardiac surgeon, perfusionists and 
intensivists and enquire about particular steps, i.e. 
preoperative transfusion, intraoperative cooling, 
postoperative plan.
•  Inform ICU, determine availability of beds.
Being mindful of the common precipitants of sickling may help 
in planning the perioperative care of the patient. As a general 
rule keep the patient warm, well hydrated and comfortable 
throughout.
Transfusion and cardiopulmonary bypass
Perioperative erythrocyte transfusion has been shown to 
decrease complications such as ACS, and is accepted practice for 
all SCD patients undergoing major surgery. A recent randomised 
controlled trial confirmed these findings, particularly in the SCA 
patients, although cardiac surgery was excluded in their 
protocol.24,26 A transfusion-free cardiac surgery has not been 
described in SCD as yet and is therefore not recommended.3
Whether to transfuse patients pre- or intraoperatively, or what 
the end points of transfusion should be is not clear.4 The bulk of 
the literature reports preoperative transfusion, either as an 
exchange transfusion or ‘top-up’ transfusion to adjust Hb levels 
and HbS concentration. Most often the goal is to achieve a 
Hb > 10 g/dl and/or HbS < 30%. An increase in adverse transfusion 
reactions is reported when the latter is targeted.27 A case series 
on three paediatric patients with SCD undergoing corrective 
cardiac surgery describes the use of intraoperative exchange 
transfusion only at the start of bypass, without any adverse 
events.7 The authors concluded: ‘We also eliminated the potential 
harm and distress for the children and their families associated 
with a preoperative exchange transfusion, which itself carries 
significant risks without any major reduction in the likelihood of 
a sickle cell crisis during surgery.’
The patients in our series often required preoperative transfusion 
to manage the acute disease and not as a prophylactic measure 
prior to surgery.
Complication Features
Auto- or alloimmunisation Common complication of recurrent erythrocyte transfusions
Haematological
Acute aplastic crisis Parvovirus B19 infections trigger acute, severe exacerbations of anaemia
Haemolytic crisis Acute anaemia often requiring erythrocyte transfusion
Splenic sequestration crisis Requires elective splenectomy when acute phase resolved
Auto-infarction of spleen 
Increased risk of systemic bacterial infection due to:
•  Defects of opsonisation
•  Phagocytic dysfunction
•  Decreased cell-mediated immunity
Table 2: (Continued)
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Adequate pain management is essential to ensure patient 
comfort and avoid conditions that may predispose patients to 
sickling.3 A combination of opiates and paracetamol is usually 
sufficient. If pain remains difficult to control postoperatively it 
may be due to an episode of vaso-occlusive crisis (VOC) or 
chronic pain related to SCD. Other analgesic modalities may 
need to be considered.12
Table 3 summarises the perioperative considerations with the 
acronym ‘SCD–CPB’.
Conclusion
Over the last decade, major cardiac surgery was performed safely 
in high-risk SCD patients at RCWMCH. To minimise the potential 
for erythrocyte sickling and adverse events in these patients, a 
thorough understanding of the pathophysiology and 
complications is essential. In each case the implications of 
erythrocyte transfusion, cardiopulmonary bypass, cardioplegia 
and cooling require special consideration and discussion with 
the surgeon, perfusionist and intensive care physician. More 
research and publications in this field would be invaluable to 
further improve the perioperative care of these patients.
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